Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ABACUS-2

ESMO 2023 2363MO: neoadjuvant atezolizumab in non-urothelial MIBC. ASCO GU 2026 abstract 832: biomarker analysis of neoadjuvant atezolizumab in UTUC from ABACUS-2. A PubMed-indexed paper and a verified utDNA numeric analysis were not found.

Urine tumor DNA